Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.415
+0.005 (0.35%)
At close: May 5, 2026, 4:00 PM EDT
1.410
-0.005 (-0.35%)
After-hours: May 5, 2026, 4:00 PM EDT
Metagenomi Therapeutics Revenue
In the year 2025, Metagenomi Therapeutics had annual revenue of $25.21M, down -51.79%. Metagenomi Therapeutics had revenue of $3.91M in the quarter ending December 31, 2025, a decrease of -59.32%.
Revenue (ttm)
$25.21M
Revenue Growth
-51.79%
P/S Ratio
2.10
Revenue / Employee
$211,849
Employees
119
Market Cap
53.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 25.21M | -27.09M | -51.79% |
| Dec 31, 2024 | 52.30M | 7.54M | 16.84% |
| Dec 31, 2023 | 44.76M | 27.56M | 160.21% |
| Dec 31, 2022 | 17.20M | 16.96M | 6,978.19% |
| Dec 31, 2021 | 243.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 43.77M |
| Sangamo Therapeutics | 39.55M |
| Radiopharm Theranostics | 10.86M |
| Rallybio | 858.00K |
| Hyperion DeFi | 813.46K |
| Entera Bio | 42.00K |
MGX News
- 19 days ago - Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency - GlobeNewsWire
- 22 days ago - Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 2 months ago - Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Metagenomi Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference - GlobeNewsWire
- 4 months ago - Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook - GlobeNewsWire
- 5 months ago - Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - GlobeNewsWire
- 5 months ago - Metagenomi Therapeutics Transcript: Jefferies London Healthcare Conference 2025 - Transcripts